Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
about
Ribosomopathies: Global process, tissue specific defectsAntibody-based immunotherapy of solid cancers: progress and possibilitiesClinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cellsHER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cellsParacrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal MelanomaImmuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical RoleExpression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma.HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancerEV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.HER3/ErbB3, an emerging cancer therapeutic target.Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.HER3 as a Therapeutic Target in Cancer.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyThe prospect of patritumab for treating non-small cell lung cancer.Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells
P2860
Q26781112-D9E0F253-98AD-4633-9AC7-F9B511A9B0BBQ26796542-EDE234EC-E41B-4355-AA03-EF1F201C3243Q27853182-8B15FC1A-9993-43E4-A231-39030E736AB6Q33412770-1773D69A-AEE1-4780-8B08-374651D4E609Q33610361-1DF38B59-B4AC-45E5-A343-F1A79F6150FFQ33887412-369B1C64-5B06-4B84-AA89-6DBC94B5159BQ35068059-E83B7808-3D20-4657-BA72-289A03F2D42FQ35201923-93DA645B-82D2-46EA-9E14-E2BCAEEE8BB0Q35812275-912DB394-4CA7-4DD5-862C-FF4D56AB91C3Q35842236-070AB0E5-8019-45D5-B961-86F4C5B8CEEEQ35987242-C19B746F-A0AC-41E3-9C07-290ADB506730Q36020920-F81BB72E-8041-4D72-B7B7-9AB353C22BBFQ36021891-6635B9CE-B0C5-4656-ADBC-50706E0F2C7AQ36547753-EB31868F-7AA8-4E10-874B-45896626F226Q36962935-D861CBEF-0ADE-43A9-B87D-F77B8C7DAA10Q37375251-49D15C87-C53B-4F79-BD56-D8ADB4F31983Q37474367-53BEF114-31F6-47A3-AE7B-BE32F1FA6317Q37515219-2050463D-27B2-4454-984D-C2F34BA4CE3DQ37578368-7F42D3A4-FDF1-4CBD-86D9-708A26E6F207Q37622191-A248E289-CDF9-4AFD-949B-910DC80DE034Q37660979-258B24B1-10E4-4528-B56F-3DA78522400AQ37692080-C38BC0C6-C36B-4973-97D6-7DB5932C4BDAQ38364887-CB55C761-09D9-43BB-ADF9-68647DDABDD8Q38573858-56D03D37-15D2-4DB6-B185-E22B146F9AD0Q38615197-10376F5C-9C4D-4DC9-B0BC-2A8578D8D593Q38623361-3D6ECF3B-6F5F-4E39-995A-EDAE716A6414Q38725101-F59525A1-897A-4668-8944-E82D73BC43E9Q38729111-648F1D32-C498-44A9-8F1B-FE697AF5DDDFQ38867798-23A9D568-F8E6-4EDA-87F9-6B687DFB8A45Q38876644-BEDBBB51-D536-4977-ACF3-66F8A74D67BAQ38929801-C3BD78D2-9B61-429C-A8FA-F37566BC19F8Q38945259-BF4BC3F5-F578-420D-BBE8-A160911144B8Q38981780-DD00A3C0-7E89-4454-A16B-D81F5F6ACADBQ39886940-02C04D00-31DD-431C-954C-EF37B7D7F493Q41173029-F54ECA92-F4C0-43F6-A2BE-FFE6A2056EA2Q47158524-5D0C9335-542D-4DF5-8A6C-790A2BA36654Q47396247-90D4D4FA-D929-4896-A6FE-342F12D047E9Q58796351-2CDFB18B-82A1-41D8-B992-FE5D689EF80A
P2860
Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Phase I study of U3-1287, a fu ...... ts with advanced solid tumors.
@en
Phase I study of U3-1287, a fu ...... ts with advanced solid tumors.
@nl
type
label
Phase I study of U3-1287, a fu ...... ts with advanced solid tumors.
@en
Phase I study of U3-1287, a fu ...... ts with advanced solid tumors.
@nl
prefLabel
Phase I study of U3-1287, a fu ...... ts with advanced solid tumors.
@en
Phase I study of U3-1287, a fu ...... ts with advanced solid tumors.
@nl
P2093
P1476
Phase I study of U3-1287, a fu ...... ts with advanced solid tumors.
@en
P2093
Abdel-Baset Halim
Catherine Copigneaux
Chi-Yuan Wu
Darrin Beaupre
Jordan Berlin
Lisa Malburg
Lorrin Yee
Moacyr Oliveira
Naiyer Rizvi
P304
P356
10.1158/1078-0432.CCR-12-3051
P407
P50
P577
2013-04-16T00:00:00Z